Skip to main content
Advanced Proteome Therapeutics Corporation logo

Advanced Proteome Therapeutics Corporation — Investor Relations & Filings

Ticker · APC.H ISIN · CA0076282098 LEI · 894500395U0H0G36UR22 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 85 across all filing types
Latest filing 2023-06-30 Regulatory Filings
Country CA Canada
Listing TSXV APC.H

About Advanced Proteome Therapeutics Corporation

www.advancedpc.ca

Advanced Proteome Therapeutics Corporation is a biotechnology company that develops and commercializes a proprietary technology platform for the chemical modification of protein therapeutics. This platform is utilized for applications in drug delivery and the redevelopment of established protein therapeutics. The company focuses on creating anti-cancer therapeutics, such as Antibody-Drug Conjugates (ADCs), by enabling the precise targeting of cancerous tumors.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification statement by the CFO of Advanced Proteome Therapeutics Corporation regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended April 30, 2023. It references Form 52-109FV2, which is a certification form related to interim filings for venture issuers. The document does not contain actual financial data or substantive financial analysis but is an officer certification of the interim filings. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3554 characters, which is relatively short and consistent with a certification letter rather than a full report.
2023-06-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification letter by the CEO of Advanced Proteome Therapeutics Corporation regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended April 30, 2023. It is identified as Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate, which is a regulatory certification related to interim filings. The document does not contain actual financial statements or substantive financial data but is a formal attestation by an officer. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3518 characters) and it is a certification, not the report itself.
2023-06-30 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis of Financial Condition and Results of Operations for the nine months ended April 30, 2023,' which clearly indicates it is a Management Discussion and Analysis (MD&A) report. It includes detailed financial data, operational results, and forward-looking statements for an interim period (nine months), consistent with an Interim / Quarterly Report. The text references unaudited interim condensed consolidated financial statements prepared under IFRS for the nine months ended April 30, 2023, and discusses financial performance, share issuances, and operational highlights. The document length is substantial (15,000 characters), and it contains substantive financial data and analysis, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2023-06-30 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Condensed Consolidated Financial Statements' for Advanced Proteome Therapeutics Corporation for the nine months ended April 30, 2023 and 2022. It contains detailed unaudited financial statements including statements of financial position, comprehensive loss, cash flows, and changes in shareholders' deficiency. The notes indicate preparation under International Accounting Standard 34 for Interim Financial Reporting. The document is approximately 15,000 characters long and contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-06-30 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Form 51-102F3 Material Change Report, which is a regulatory filing used to disclose significant corporate events or changes. It details a material change involving a Plan of Arrangement, shareholder meeting, and related corporate restructuring. The document is relatively short (3064 characters) and provides a formal announcement of the material change rather than a full report or financial statements. It does not contain comprehensive financial data or detailed management discussion, nor is it a proxy solicitation or voting results announcement. Given these characteristics, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-19 English
Notice of the meeting and record date (amended) - English.pdf
Regulatory Filings Classification · 90% confidence The document is a notice regarding the upcoming Annual & Special Meeting of Security Holders for Advanced Proteome Therapeutics Corporation. It provides details such as meeting type, record dates, meeting date and location, and voting securities information. The document does not contain financial statements, management discussion, or detailed report content. It is an announcement about the meeting and related record dates rather than the meeting materials or results themselves. Given the short length (1319 characters) and the nature of the content, this fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly a Proxy Solicitation & Information Statement (PSI). However, since it is a notice of meeting and record dates (pre-meeting announcement), it is best classified as a Regulatory Filing (RNS) because it does not provide proxy materials or voting results but is a general regulatory announcement about the meeting schedule. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-01-12 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.